{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:47:39Z","timestamp":1773294459800,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,3,3]],"date-time":"2011-03-03T00:00:00Z","timestamp":1299110400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1007\/s11940-011-0117-x","type":"journal-article","created":{"date-parts":[[2011,3,3]],"date-time":"2011-03-03T10:05:12Z","timestamp":1299146712000},"page":"231-241","source":"Crossref","is-referenced-by-count":37,"title":["Tardive Dyskinesia"],"prefix":"10.1007","volume":"13","author":[{"given":"Pratibha G.","family":"Aia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gonzalo J.","family":"Revuelta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie J.","family":"Cloud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stewart A.","family":"Factor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,3,3]]},"reference":[{"key":"117_CR1","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/ajp.117.2.152","volume":"117","author":"W Kruse","year":"1960","unstructured":"Kruse W. Persistent muscular restlessness after phenothiazine treatment: report of 3 cases. Am J Psychiatry. 1960;117:152\u20133.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"117_CR2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/YCO.0b013e3282f53132","volume":"21","author":"CU Correll","year":"2008","unstructured":"Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008;21(2):151\u20136.","journal-title":"Curr Opin Psychiatry"},{"issue":"2","key":"117_CR3","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/1531-8257(200003)15:2<352::AID-MDS1030>3.0.CO;2-X","volume":"15","author":"A Rapaport","year":"2000","unstructured":"Rapaport A, et al. Botulinum toxin for the treatment of oro-facial-lingual-masticatory tardive dyskinesia. Mov Disord. 2000;15(2):352\u20135.","journal-title":"Mov Disord"},{"issue":"6500","key":"117_CR4","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1136\/bmj.291.6500.930","volume":"291","author":"DN Bateman","year":"1985","unstructured":"Bateman DN, Rawlins MD, Simpson JM. Extrapyramidal reactions with metoclopramide. Br Med J (Clin Res Ed). 1985;291(6500):930\u20132.","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"6416","key":"117_CR5","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/bmj.288.6416.545","volume":"288","author":"BE Wiholm","year":"1984","unstructured":"Wiholm BE, et al. Tardive dyskinesia associated with metoclopramide. Br Med J (Clin Res Ed). 1984;288(6416):545\u20137.","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"7","key":"117_CR6","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1001\/archpsyc.1982.04290070037008","volume":"39","author":"DV Jeste","year":"1982","unstructured":"Jeste DV, Wyatt RJ. Therapeutic strategies against tardive dyskinesia. Two decades of experience. Arch Gen Psychiatry. 1982;39(7):803\u201316.","journal-title":"Arch Gen Psychiatry"},{"issue":"4 Suppl","key":"117_CR7","first-page":"52S","volume":"8","author":"JM Kane","year":"1988","unstructured":"Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol. 1988;8(4 Suppl):52S\u20136S.","journal-title":"J Clin Psychopharmacol"},{"key":"117_CR8","unstructured":"Marsden CD, MRHS, Baldessarini RJ. Extrapyramidal movement disorders produced by antipsychotic drugs. In: Hirsch SR, Bradley PB, editors. Pharmacology and Treatment of Schizophrenia. London: Oxford; 1986."},{"issue":"6","key":"117_CR9","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1176\/ajp.150.6.966","volume":"150","author":"MG Woerner","year":"1993","unstructured":"Woerner MG, et al. Diabetes and development of tardive dyskinesia. Am J Psychiatry. 1993;150(6):966\u20138.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"117_CR10","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/schbul\/18.4.701","volume":"18","author":"R Yassa","year":"1992","unstructured":"Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull. 1992;18(4):701\u201315.","journal-title":"Schizophr Bull"},{"issue":"11","key":"117_CR11","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1212\/WNL.39.11.1434","volume":"39","author":"PM FitzGerald","year":"1989","unstructured":"FitzGerald PM, Jankovic J. Tardive oculogyric crises. Neurology. 1989;39(11):1434\u20137.","journal-title":"Neurology"},{"key":"117_CR12","volume-title":"Principles and practice of movement disorders","author":"S Fahn","year":"2007","unstructured":"Fahn S, Jankovic J. Principles and practice of movement disorders. Philadelphia: Churchill Livingstone; 2007."},{"issue":"2","key":"117_CR13","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1017\/S031716710003033X","volume":"17","author":"AE Lang","year":"1990","unstructured":"Lang AE. Clinical differences between metoclopramide- and antipsychotic-induced tardive dyskinesias. Can J Neurol Sci. 1990;17(2):137\u20139.","journal-title":"Can J Neurol Sci"},{"issue":"2","key":"117_CR14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/mds.870020207","volume":"2","author":"MR Samie","year":"1987","unstructured":"Samie MR, Dannenhoffer MA, Rozek S. Life-threatening tardive dyskinesia caused by metoclopramide. Mov Disord. 1987;2(2):125\u20139.","journal-title":"Mov Disord"},{"issue":"2","key":"117_CR15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00004850-199903000-00010","volume":"14","author":"J Horiguchi","year":"1999","unstructured":"Horiguchi J, et al. Antipsychotic-induced life-threatening \u2018esophageal dyskinesia\u2019. Int Clin Psychopharmacol. 1999;14(2):123\u20137.","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"117_CR16","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1600-0447.1997.tb10151.x","volume":"96","author":"LA Labbate","year":"1997","unstructured":"Labbate LA, et al. Tardive dyskinesia in older out-patients: a follow-up study. Acta Psychiatr Scand. 1997;96(3):195\u20138.","journal-title":"Acta Psychiatr Scand"},{"issue":"17","key":"117_CR17","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1517\/14656560903386292","volume":"10","author":"A Fasano","year":"2009","unstructured":"\u2022 Fasano A, Bentivoglio AR. Tetrabenazine. Expert Opin Pharmacother. 2009;10(17):2883\u201396.","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"117_CR18","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","volume":"66","author":"Huntington Study Group","year":"2006","unstructured":"Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66(3):366\u201372.","journal-title":"Neurology"},{"issue":"8","key":"117_CR19","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1176\/ajp.156.8.1279","volume":"156","author":"WG Ondo","year":"1999","unstructured":"Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry. 1999;156(8):1279\u201381.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"117_CR20","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/mds.21222","volume":"22","author":"C Kenney","year":"2007","unstructured":"Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007;22(2):193\u20137.","journal-title":"Mov Disord"},{"issue":"3","key":"117_CR21","first-page":"41","volume":"16","author":"CC Huang","year":"1980","unstructured":"Huang CC, et al. Evaluation of reserpine and alpha-methyldopa in the treatment of tardive dyskinesia. Psychopharmacol Bull. 1980;16(3):41\u20133.","journal-title":"Psychopharmacol Bull"},{"issue":"4","key":"117_CR22","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/BF00426466","volume":"73","author":"CC Huang","year":"1981","unstructured":"Huang CC, et al. Reserpine and alpha-methyldopa in the treatment of tardive dyskinesia. Psychopharmacol Berl. 1981;73(4):359\u201362.","journal-title":"Psychopharmacology (Berl)"},{"issue":"4 Pt 2","key":"117_CR23","first-page":"19","volume":"46","author":"S Fahn","year":"1985","unstructured":"Fahn S. A therapeutic approach to tardive dyskinesia. J Clin Psychiatry. 1985;46(4 Pt 2):19\u201324.","journal-title":"J Clin Psychiatry"},{"key":"117_CR24","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1192\/bjp.158.4.503","volume":"158","author":"JA Lieberman","year":"1991","unstructured":"Lieberman JA, et al. The effects of clozapine on tardive dyskinesia. Br J Psychiatry. 1991;158:503\u201310.","journal-title":"Br J Psychiatry"},{"issue":"5","key":"117_CR25","first-page":"196","volume":"44","author":"NA Bacher","year":"1983","unstructured":"Bacher NA, Lewis HA. Propranolol, anxiety, and tardive dyskinesia. J Clin Psychiatry. 1983;44(5):196.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"117_CR26","first-page":"391","volume":"18","author":"A Perenyi","year":"1983","unstructured":"Perenyi A, Farkas A. Propranolol in the treatment of tardive-dyskinesia. Biol Psychiatry. 1983;18(3):391\u20134.","journal-title":"Biol Psychiatry"},{"issue":"8","key":"117_CR27","first-page":"304","volume":"43","author":"FN Pitts","year":"1982","unstructured":"Pitts FN. Treatment of tardive-dyskinesia with propranolol. J Clin Psychiatry. 1982;43(8):304\u20134.","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"117_CR28","first-page":"328","volume":"43","author":"GR Schrodt","year":"1982","unstructured":"Schrodt GR, et al. Treatment of tardive-dyskinesia with propranolol. J Clin Psychiatry. 1982;43(8):328\u201331.","journal-title":"J Clin Psychiatry"},{"key":"117_CR29","doi-asserted-by":"crossref","unstructured":"Soares KV, McGrath JJ. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2000;(2):CD000209.","DOI":"10.1002\/14651858.CD000206"},{"issue":"9","key":"117_CR30","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1176\/ajp.150.9.1405","volume":"150","author":"LA Adler","year":"1993","unstructured":"Adler LA, et al. Vitamin E treatment of tardive dyskinesia. Am J Psychiatry. 1993;150(9):1405\u20137.","journal-title":"Am J Psychiatry"},{"issue":"9","key":"117_CR31","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/archpsyc.56.9.836","volume":"56","author":"LA Adler","year":"1999","unstructured":"Adler LA, et al. Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group. Arch Gen Psychiatry. 1999;56(9):836\u201341.","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"117_CR32","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1176\/ajp.147.4.445","volume":"147","author":"GK Thaker","year":"1990","unstructured":"Thaker GK, et al. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry. 1990;147(4):445\u201351.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"117_CR33","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1176\/ajp.138.2.189","volume":"138","author":"A Bobruff","year":"1981","unstructured":"Bobruff A, et al. Clonazepam and phenobarbital in tardive dyskinesia. Am J Psychiatry. 1981;138(2):189\u201393.","journal-title":"Am J Psychiatry"},{"issue":"6","key":"117_CR34","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/WNF.0b013e3181ffde32","volume":"33","author":"S Pappa","year":"2010","unstructured":"\u2022 Pappa S, et al. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2010;33(6):271\u20135.","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"117_CR35","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/00004714-199704000-00004","volume":"17","author":"S Angus","year":"1997","unstructured":"Angus S, et al. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol. 1997;17(2):88\u201391.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"117_CR36","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4088\/JCP.v69n0405","volume":"69","author":"SW Woods","year":"2008","unstructured":"Woods SW, et al. Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2008;69(4):546\u201354.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"117_CR37","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.pnpbp.2007.10.004","volume":"32","author":"CW Slotema","year":"2008","unstructured":"Slotema CW, et al. Botulinum toxin in the treatment of orofacial tardive dyskinesia: a single blind study. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(2):507\u20139.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"7","key":"117_CR38","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.parkreldis.2010.04.007","volume":"16","author":"CD Esper","year":"2010","unstructured":"Esper CD, Freeman A, Factor SA. Lingual protrusion dystonia: frequency, etiology and botulinum toxin therapy. Parkinsonism Relat Disord. 2010;16(7):438\u201341.","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"117_CR39","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.pnpbp.2007.09.010","volume":"32","author":"JM Hennings","year":"2008","unstructured":"Hennings JM, B\u00f6tzel KE, Wetter TC. Successful treatment of tardive lingual dystonia with botulinum toxin: case report and review of the literature. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(5):1167\u201371.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"4","key":"117_CR40","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/WCO.0b013e32833b7798","volume":"23","author":"ML Welter","year":"2010","unstructured":"Welter ML, Grabli D, Vidailhet M. Deep brain stimulation for hyperkinetics disorders: dystonia, tardive dyskinesia, and tics. Curr Opin Neurol. 2010;23(4):420\u20135.","journal-title":"Curr Opin Neurol"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-011-0117-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-011-0117-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-011-0117-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T18:32:41Z","timestamp":1712255561000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-011-0117-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,3]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["117"],"URL":"https:\/\/doi.org\/10.1007\/s11940-011-0117-x","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,3]]}}}